Tag Archives: development
#437548 Curved origami provides new range of ...
New research that employs curved origami structures has dramatic implications in the development of robotics going forward, providing tunable flexibility—the ability to adjust stiffness based on function—that historically has been difficult to achieve using simple design. Continue reading
Posted in Human Robots
#437337 6G Will Be 100 Times Faster Than ...
Though 5G—a next-generation speed upgrade to wireless networks—is scarcely up and running (and still nonexistent in many places) researchers are already working on what comes next. It lacks an official name, but they’re calling it 6G for the sake of simplicity (and hey, it’s tradition). 6G promises to be up to 100 times faster than 5G—fast enough to download 142 hours of Netflix in a second—but researchers are still trying to figure out exactly how to make such ultra-speedy connections happen.
A new chip, described in a paper in Nature Photonics by a team from Osaka University and Nanyang Technological University in Singapore, may give us a glimpse of our 6G future. The team was able to transmit data at a rate of 11 gigabits per second, topping 5G’s theoretical maximum speed of 10 gigabits per second and fast enough to stream 4K high-def video in real time. They believe the technology has room to grow, and with more development, might hit those blistering 6G speeds.
NTU final year PhD student Abhishek Kumar, Assoc Prof Ranjan Singh and postdoc Dr Yihao Yang. Dr Singh is holding the photonic topological insulator chip made from silicon, which can transmit terahertz waves at ultrahigh speeds. Credit: NTU Singapore
But first, some details about 5G and its predecessors so we can differentiate them from 6G.
Electromagnetic waves are characterized by a wavelength and a frequency; the wavelength is the distance a cycle of the wave covers (peak to peak or trough to trough, for example), and the frequency is the number of waves that pass a given point in one second. Cellphones use miniature radios to pick up electromagnetic signals and convert those signals into the sights and sounds on your phone.
4G wireless networks run on millimeter waves on the low- and mid-band spectrum, defined as a frequency of a little less (low-band) and a little more (mid-band) than one gigahertz (or one billion cycles per second). 5G kicked that up several notches by adding even higher frequency millimeter waves of up to 300 gigahertz, or 300 billion cycles per second. Data transmitted at those higher frequencies tends to be information-dense—like video—because they’re much faster.
The 6G chip kicks 5G up several more notches. It can transmit waves at more than three times the frequency of 5G: one terahertz, or a trillion cycles per second. The team says this yields a data rate of 11 gigabits per second. While that’s faster than the fastest 5G will get, it’s only the beginning for 6G. One wireless communications expert even estimates 6G networks could handle rates up to 8,000 gigabits per second; they’ll also have much lower latency and higher bandwidth than 5G.
Terahertz waves fall between infrared waves and microwaves on the electromagnetic spectrum. Generating and transmitting them is difficult and expensive, requiring special lasers, and even then the frequency range is limited. The team used a new material to transmit terahertz waves, called photonic topological insulators (PTIs). PTIs can conduct light waves on their surface and edges rather than having them run through the material, and allow light to be redirected around corners without disturbing its flow.
The chip is made completely of silicon and has rows of triangular holes. The team’s research showed the chip was able to transmit terahertz waves error-free.
Nanyang Technological University associate professor Ranjan Singh, who led the project, said, “Terahertz technology […] can potentially boost intra-chip and inter-chip communication to support artificial intelligence and cloud-based technologies, such as interconnected self-driving cars, which will need to transmit data quickly to other nearby cars and infrastructure to navigate better and also to avoid accidents.”
Besides being used for AI and self-driving cars (and, of course, downloading hundreds of hours of video in seconds), 6G would also make a big difference for data centers, IoT devices, and long-range communications, among other applications.
Given that 5G networks are still in the process of being set up, though, 6G won’t be coming on the scene anytime soon; a recent whitepaper on 6G from Japanese company NTTDoCoMo estimates we’ll see it in 2030, pointing out that wireless connection tech generations have thus far been spaced about 10 years apart; we got 3G in the early 2000s, 4G in 2010, and 5G in 2020.
In the meantime, as 6G continues to develop, we’re still looking forward to the widespread adoption of 5G.
Image Credit: Hans Braxmeier from Pixabay Continue reading
Posted in Human Robots
#437269 DeepMind’s Newest AI Programs Itself ...
When Deep Blue defeated world chess champion Garry Kasparov in 1997, it may have seemed artificial intelligence had finally arrived. A computer had just taken down one of the top chess players of all time. But it wasn’t to be.
Though Deep Blue was meticulously programmed top-to-bottom to play chess, the approach was too labor-intensive, too dependent on clear rules and bounded possibilities to succeed at more complex games, let alone in the real world. The next revolution would take a decade and a half, when vastly more computing power and data revived machine learning, an old idea in artificial intelligence just waiting for the world to catch up.
Today, machine learning dominates, mostly by way of a family of algorithms called deep learning, while symbolic AI, the dominant approach in Deep Blue’s day, has faded into the background.
Key to deep learning’s success is the fact the algorithms basically write themselves. Given some high-level programming and a dataset, they learn from experience. No engineer anticipates every possibility in code. The algorithms just figure it.
Now, Alphabet’s DeepMind is taking this automation further by developing deep learning algorithms that can handle programming tasks which have been, to date, the sole domain of the world’s top computer scientists (and take them years to write).
In a paper recently published on the pre-print server arXiv, a database for research papers that haven’t been peer reviewed yet, the DeepMind team described a new deep reinforcement learning algorithm that was able to discover its own value function—a critical programming rule in deep reinforcement learning—from scratch.
Surprisingly, the algorithm was also effective beyond the simple environments it trained in, going on to play Atari games—a different, more complicated task—at a level that was, at times, competitive with human-designed algorithms and achieving superhuman levels of play in 14 games.
DeepMind says the approach could accelerate the development of reinforcement learning algorithms and even lead to a shift in focus, where instead of spending years writing the algorithms themselves, researchers work to perfect the environments in which they train.
Pavlov’s Digital Dog
First, a little background.
Three main deep learning approaches are supervised, unsupervised, and reinforcement learning.
The first two consume huge amounts of data (like images or articles), look for patterns in the data, and use those patterns to inform actions (like identifying an image of a cat). To us, this is a pretty alien way to learn about the world. Not only would it be mind-numbingly dull to review millions of cat images, it’d take us years or more to do what these programs do in hours or days. And of course, we can learn what a cat looks like from just a few examples. So why bother?
While supervised and unsupervised deep learning emphasize the machine in machine learning, reinforcement learning is a bit more biological. It actually is the way we learn. Confronted with several possible actions, we predict which will be most rewarding based on experience—weighing the pleasure of eating a chocolate chip cookie against avoiding a cavity and trip to the dentist.
In deep reinforcement learning, algorithms go through a similar process as they take action. In the Atari game Breakout, for instance, a player guides a paddle to bounce a ball at a ceiling of bricks, trying to break as many as possible. When playing Breakout, should an algorithm move the paddle left or right? To decide, it runs a projection—this is the value function—of which direction will maximize the total points, or rewards, it can earn.
Move by move, game by game, an algorithm combines experience and value function to learn which actions bring greater rewards and improves its play, until eventually, it becomes an uncanny Breakout player.
Learning to Learn (Very Meta)
So, a key to deep reinforcement learning is developing a good value function. And that’s difficult. According to the DeepMind team, it takes years of manual research to write the rules guiding algorithmic actions—which is why automating the process is so alluring. Their new Learned Policy Gradient (LPG) algorithm makes solid progress in that direction.
LPG trained in a number of toy environments. Most of these were “gridworlds”—literally two-dimensional grids with objects in some squares. The AI moves square to square and earns points or punishments as it encounters objects. The grids vary in size, and the distribution of objects is either set or random. The training environments offer opportunities to learn fundamental lessons for reinforcement learning algorithms.
Only in LPG’s case, it had no value function to guide that learning.
Instead, LPG has what DeepMind calls a “meta-learner.” You might think of this as an algorithm within an algorithm that, by interacting with its environment, discovers both “what to predict,” thereby forming its version of a value function, and “how to learn from it,” applying its newly discovered value function to each decision it makes in the future.
Prior work in the area has had some success, but according to DeepMind, LPG is the first algorithm to discover reinforcement learning rules from scratch and to generalize beyond training. The latter was particularly surprising because Atari games are so different from the simple worlds LPG trained in—that is, it had never seen anything like an Atari game.
Time to Hand Over the Reins? Not Just Yet
LPG is still behind advanced human-designed algorithms, the researchers said. But it outperformed a human-designed benchmark in training and even some Atari games, which suggests it isn’t strictly worse, just that it specializes in some environments.
This is where there’s room for improvement and more research.
The more environments LPG saw, the more it could successfully generalize. Intriguingly, the researchers speculate that with enough well-designed training environments, the approach might yield a general-purpose reinforcement learning algorithm.
At the least, though, they say further automation of algorithm discovery—that is, algorithms learning to learn—will accelerate the field. In the near term, it can help researchers more quickly develop hand-designed algorithms. Further out, as self-discovered algorithms like LPG improve, engineers may shift from manually developing the algorithms themselves to building the environments where they learn.
Deep learning long ago left Deep Blue in the dust at games. Perhaps algorithms learning to learn will be a winning strategy in the real world too.
Image credit: Mike Szczepanski / Unsplash Continue reading
Posted in Human Robots
#437261 How AI Will Make Drug Discovery ...
If you had to guess how long it takes for a drug to go from an idea to your pharmacy, what would you guess? Three years? Five years? How about the cost? $30 million? $100 million?
Well, here’s the sobering truth: 90 percent of all drug possibilities fail. The few that do succeed take an average of 10 years to reach the market and cost anywhere from $2.5 billion to $12 billion to get there.
But what if we could generate novel molecules to target any disease, overnight, ready for clinical trials? Imagine leveraging machine learning to accomplish with 50 people what the pharmaceutical industry can barely do with an army of 5,000.
Welcome to the future of AI and low-cost, ultra-fast, and personalized drug discovery. Let’s dive in.
GANs & Drugs
Around 2012, computer scientist-turned-biophysicist Alex Zhavoronkov started to notice that artificial intelligence was getting increasingly good at image, voice, and text recognition. He knew that all three tasks shared a critical commonality. In each, massive datasets were available, making it easy to train up an AI.
But similar datasets were present in pharmacology. So, back in 2014, Zhavoronkov started wondering if he could use these datasets and AI to significantly speed up the drug discovery process. He’d heard about a new technique in artificial intelligence known as generative adversarial networks (or GANs). By pitting two neural nets against one another (adversarial), the system can start with minimal instructions and produce novel outcomes (generative). At the time, researchers had been using GANs to do things like design new objects or create one-of-a-kind, fake human faces, but Zhavoronkov wanted to apply them to pharmacology.
He figured GANs would allow researchers to verbally describe drug attributes: “The compound should inhibit protein X at concentration Y with minimal side effects in humans,” and then the AI could construct the molecule from scratch. To turn his idea into reality, Zhavoronkov set up Insilico Medicine on the campus of Johns Hopkins University in Baltimore, Maryland, and rolled up his sleeves.
Instead of beginning their process in some exotic locale, Insilico’s “drug discovery engine” sifts millions of data samples to determine the signature biological characteristics of specific diseases. The engine then identifies the most promising treatment targets and—using GANs—generates molecules (that is, baby drugs) perfectly suited for them. “The result is an explosion in potential drug targets and a much more efficient testing process,” says Zhavoronkov. “AI allows us to do with fifty people what a typical drug company does with five thousand.”
The results have turned what was once a decade-long war into a month-long skirmish.
In late 2018, for example, Insilico was generating novel molecules in fewer than 46 days, and this included not just the initial discovery, but also the synthesis of the drug and its experimental validation in computer simulations.
Right now, they’re using the system to hunt down new drugs for cancer, aging, fibrosis, Parkinson’s, Alzheimer’s, ALS, diabetes, and many others. The first drug to result from this work, a treatment for hair loss, is slated to start Phase I trials by the end of 2020.
They’re also in the early stages of using AI to predict the outcomes of clinical trials in advance of the trial. If successful, this technique will enable researchers to strip a bundle of time and money out of the traditional testing process.
Protein Folding
Beyond inventing new drugs, AI is also being used by other scientists to identify new drug targets—that is, the place to which a drug binds in the body and another key part of the drug discovery process.
Between 1980 and 2006, despite an annual investment of $30 billion, researchers only managed to find about five new drug targets a year. The trouble is complexity. Most potential drug targets are proteins, and a protein’s structure—meaning the way a 2D sequence of amino acids folds into a 3D protein—determines its function.
But a protein with merely a hundred amino acids (a rather small protein) can produce a googol-cubed worth of potential shapes—that’s a one followed by three hundred zeroes. This is also why protein-folding has long been considered an intractably hard problem for even the most powerful of supercomputers.
Back in 1994, to monitor supercomputers’ progress in protein-folding, a biannual competition was created. Until 2018, success was fairly rare. But then the creators of DeepMind turned their neural networks loose on the problem. They created an AI that mines enormous datasets to determine the most likely distance between a protein’s base pairs and the angles of their chemical bonds—aka, the basics of protein-folding. They called it AlphaFold.
On its first foray into the competition, contestant AIs were given 43 protein-folding problems to solve. AlphaFold got 25 right. The second-place team managed a meager three. By predicting the elusive ways in which various proteins fold on the basis of their amino acid sequences, AlphaFold may soon have a tremendous impact in aiding drug discovery and fighting some of today’s most intractable diseases.
Drug Delivery
Another theater of war for improved drugs is the realm of drug delivery. Even here, converging exponential technologies are paving the way for massive implications in both human health and industry shifts.
One key contender is CRISPR, the fast-advancing gene-editing technology that stands to revolutionize synthetic biology and treatment of genetically linked diseases. And researchers have now demonstrated how this tool can be applied to create materials that shape-shift on command. Think: materials that dissolve instantaneously when faced with a programmed stimulus, releasing a specified drug at a highly targeted location.
Yet another potential boon for targeted drug delivery is nanotechnology, whereby medical nanorobots have now been used to fight incidences of cancer. In a recent review of medical micro- and nanorobotics, lead authors (from the University of Texas at Austin and University of California, San Diego) found numerous successful tests of in vivo operation of medical micro- and nanorobots.
Drugs From the Future
Covid-19 is uniting the global scientific community with its urgency, prompting scientists to cast aside nation-specific territorialism, research secrecy, and academic publishing politics in favor of expedited therapeutic and vaccine development efforts. And in the wake of rapid acceleration across healthcare technologies, Big Pharma is an area worth watching right now, no matter your industry. Converging technologies will soon enable extraordinary strides in longevity and disease prevention, with companies like Insilico leading the charge.
Riding the convergence of massive datasets, skyrocketing computational power, quantum computing, cognitive surplus capabilities, and remarkable innovations in AI, we are not far from a world in which personalized drugs, delivered directly to specified targets, will graduate from science fiction to the standard of care.
Rejuvenational biotechnology will be commercially available sooner than you think. When I asked Alex for his own projection, he set the timeline at “maybe 20 years—that’s a reasonable horizon for tangible rejuvenational biotechnology.”
How might you use an extra 20 or more healthy years in your life? What impact would you be able to make?
Join Me
(1) A360 Executive Mastermind: If you’re an exponentially and abundance-minded entrepreneur who would like coaching directly from me, consider joining my Abundance 360 Mastermind, a highly selective community of 360 CEOs and entrepreneurs who I coach for 3 days every January in Beverly Hills, Ca. Through A360, I provide my members with context and clarity about how converging exponential technologies will transform every industry. I’m committed to running A360 for the course of an ongoing 25-year journey as a “countdown to the Singularity.”
If you’d like to learn more and consider joining our 2021 membership, apply here.
(2) Abundance-Digital Online Community: I’ve also created a Digital/Online community of bold, abundance-minded entrepreneurs called Abundance-Digital. Abundance-Digital is Singularity University’s ‘onramp’ for exponential entrepreneurs—those who want to get involved and play at a higher level. Click here to learn more.
(Both A360 and Abundance-Digital are part of Singularity University—your participation opens you to a global community.)
This article originally appeared on diamandis.com. Read the original article here.
Image Credit: andreas160578 from Pixabay Continue reading
Posted in Human Robots